Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939), a specializing in AI-driven healthcare solutions, has made significant strides with the announcement of two innovative products set to revolutionize medical education: AI Patient and AI Doctor in a Pocket. These new solutions are part of the company's comprehensive Medical Education Suite (MES), which is designed to prepare the next generation of healthcare professionals with cutting-edge tools and resources.
Elevating Medical Education
Treatment's MES is tailored to enhance clinical content education across the board, from basic patient interactions to advanced USMLE diagnostic evaluations and faculty benchmarking. By reducing faculty administration costs and time, the MES provides a broad spectrum of clinical experiences and offers students a digital self-test companion to deepen their diagnostic skills. The suite supports both students and faculty in preparing for the Objective Structured Clinical Examination (OSCE), a critical test used in 57 countries to assess the practical reasoning and diagnostic abilities of healthcare students.
A Growing Market
The U.S. alone has a significant market potential with 300 medical schools, 900 nursing schools, and a combined 372,000 medical and nursing students. Treatment.com is also expanding its discussions to include schools in the UK and Canada, indicating a broadening international reach.
Introducing AI Patient and AI Doctor in a Pocket
Set to launch in the second half of 2024, AI Patient and AI Doctor in a Pocket are monthly subscription-based SaaS solutions aimed at students, residents, and healthcare professionals.
- AI Patient utilizes AI and a robust library of test cases to help students prepare for multiple-choice questions (MCQs) and OSCE exams, ensuring they are well-prepared for critical evaluations.
- AI Doctor in a Pocket offers a mobile-friendly AI-powered clinical decision support tool, providing healthcare professionals and students with vital information and support during clinical practice.
Both solutions are underpinned by Treatment’s proprietary Global Library of Medicine (GLM), an extensive online medical library created with input from hundreds of credentialed clinicians worldwide, ensuring high-quality clinical information and support.
Leadership and Vision
Dr. Essam Hamza, CEO of Treatment.com AI, expressed his enthusiasm for the new solutions, highlighting their potential to support students throughout their education and into their professional practice. "Our goal is for students to be supported and excel during their medical education, and then utilize the same trusted platform as they move into practice," he stated.
Strategic Growth and Contract Renewals
Adding to the momentum, Treatment.com recently announced a contract renewal with a leading U.S. medical school for its MES. This renewal underscores the growing pipeline and strong market demand for Treatment’s solutions. The MES aims to streamline the creation, administration, and grading of national exams such as the OSCE, reducing costs and administrative burden for medical schools.
New Executive Appointment
In a move to further bolster its leadership, Treatment.com appointed Richard Atkins as Chief Operating Officer. With over 30 years of experience in international sales, partnerships, executive management, and M&A, Atkins brings a wealth of knowledge to the team. His extensive background in healthcare technology, including work with major health-tech firms and innovative digital health solutions, positions him to accelerate Treatment's expansion and commercialization efforts.
Dr. Hamza welcomed Atkins to the executive team, noting, "Richard understands the unique inflection point of our company and has committed to help with the execution of our aggressive commercialization phase."
Overall, Treatment.com AI Inc (CSE: TRUE) continues to make significant advances in the field of medical education and healthcare technology. With the introduction of AI Patient and AI Doctor in a Pocket, the company is poised to support the next generation of healthcare professionals in unprecedented ways. As they expand their reach and enhance their offerings, investors and traders should keep a close watch on Treatment.com’s developments, as these innovations could lead to substantial growth and market impact.
The global artificial intelligence (AI) in healthcare market size was estimated at USD 15.1 billion in 2022 and it is expected to surpass around USD 187.95 billion by 2030, growing at a CAGR of 37% during the forecast period 2022 to 2030. North America AI in healthcare market was valued at USD 6.8 billion in 2022. This suggests that companies with a viable healthcare-related AI product could benefit from the growing use of AI in healthcare.
Other Health Care AI Stocks to keep an eye out include HEALWELL AI Inc (TSX: AIDX), HEALWELL AI Inc (OTCQX: HWAIF), Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), GE HealthCare Technologies Inc. (NASDAQ: GEHC), VERSES AI Inc (OTCMKTS: VRSSF), VERSES AI Inc (CBOE: VERS)
Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.
Sources:
https://finance.yahoo.com/news/treatment-com-ai-welcomes-federal-120000957.html
https://www.cbc.ca/news/politics/federal-government-ai-investment-1.7166234
https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html
https://ca.finance.yahoo.com/news/healwell-ai-pentavere-achieves-validation-110000955.html
https://finance.yahoo.com/quote/TRUE.CN/
https://finance.yahoo.com/news/repeat-treatment-com-ai-announces-120000231.html
https://www.precedenceresearch.com/artificial-intelligence-in-healthcare-market#:~:text=The%20global%20artificial%20intelligence%20(AI,forecast%20period%202022%20to%202030.
Media Contact
Company Name: TheBullReport
Contact Person: Ward Abbott
Email: info@thebullreport.com
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/
